Case‐finding tools for the diagnosis of OAB in women: A narrative review

Malde, Sachin; Kelly, Samuel; Saad, Sanad; Sahai, Amit

doi:10.1002/nau.24171

Cited by 5 publications

(4 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although our sample size is limited, it does not rule out the clinically significant impact of mirabegron and solifenacin combination treatment in the OABSS score. In addition, although results were evaluated by a subjective assessment tool as OABSS, this is a valuable assessment, which has a widespread use in the literature 24 …”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and Safety of Mirabegron Add-on Therapy After Failure With Solifenacin in Multiple Sclerosis Patients With Overactive Bladder: A Pilot Study

Mut,

Selcuk,

İncirli

et al. 2024

Clin Neuropharm

View full text Add to dashboard Cite

Objectives Multiple sclerosis (MS) is a chronic neuroinflammatory and neurodegenerative progressive disease of central nervous system that mostly affects young adults. (1) Because of involvement of spinal cord and brain, lower urinary dysfunction symptoms are commonly encountered. MS patients mostly show overactive bladder symptoms like urgency, frequent daytime urination, and urgency incontinence. Among MS patients, antimuscarinic therapy is the first-line treatment with overactive bladder symptoms as well as in general population yet 30% of the patients show insufficient improvement or intolerance to the treatment (2). In our study, our aim is to evaluate the efficacy and safety of mirabegron add-on treatment in MS patients after inadequate response to antimuscarinic monotherapy. Methods University of Kyrenia and Dr Burhan Nalbantoglu State hospital's databases were screened for the study. Seventy patients who were residents diagnosed with MS according to McDonald criteria were questioned. Among these patients, a total of 22 of them were included in the study. Inclusion criteria was at least 3 years of MS diagnosis, score of <6 at Expanded Disability Status Scale, and a score of ≥3 at Overactive Bladder Symptom Score Scale. Results Among selected patients, 10 mg solifenacin treatment was daily started and followed for 4 weeks. Mirabegron add-on treatment was initiated to the 11 patient who had inadequate improvement in overactive bladder symptom score. After mirabegron add-on treatment among 11 patient, there was a sufficient improvement in overactive bladder symptom score (P < 0.008). Conclusions In our study, we have found that antimuscarinic and mirabegron combination causes improved efficacy for overactive bladder in MS population.

show abstract

Section: Discussionmentioning

confidence: 99%

“…In addition, although results were evaluated by a subjective assessment tool as OABSS, this is a valuable assessment, which has a widespread use in the literature. 24…”

Section: Discussionmentioning

confidence: 99%

Efficacy and Safety of Mirabegron Add-on Therapy After Failure With Solifenacin in Multiple Sclerosis Patients With Overactive Bladder: A Pilot Study

Mut,

Selcuk,

İncirli

et al. 2024

Clin Neuropharm

View full text Add to dashboard Cite

show abstract

“…The OAB-V8 was used to assess symptom severity in women, and the questionnaire measures the degree of bothersomeness of four symptoms associated with OAB: urinary frequency, urgency, nocturia, and urge incontinence, with a total score between 0 and 40 [13].…”

Section: Evaluation Parametersmentioning

confidence: 99%

Efficacy of the combination of transcutaneous tibial nerve stimulation(TTNS) and mirabegron in women with overactive bladder: a prospective randomized controlled trial

Xu,

Xiong,

Tian

et al. 2024

Preprint

View full text Add to dashboard Cite

Objective: The management of overactive bladder (OAB) in women encompasses a range of strategies, from behavioral modifications to pharmacotherapy and nerve stimulation techniques. This prospective, randomized, controlled trial evaluates the efficacy of the combination of TTNS and mirabegron in symptom improvement over three months in women diagnosed with OAB. Patients and Methods: The study was designed as a randomized controlled trial. A total of 40 patients were prospectively randomized into two groups. Twenty patients in the combination group accepted TTNS and mirabegron therapy, and the other 20 patients as control only accepted mirabegron therapy. Primary outcomes were changes from baseline in the lower urinary tract symptoms. The severity of symptoms and quality of life (QoL) were assessed using the validated OAB questionnaire (OAB-q). Results: TTNS reduced the clinical symptoms of OAB, and the difference was statistically significant at all study sites (p<0.05). Regarding secondary outcomes, the OAB-q symptom bother score was lower in the combination group than in the mirabegron group (p<0.05). The OAB-q score in the combination group was statistically superior to that in the mirabegron group (p<0.05). The incidence of complications was not statistically significant between the two groups. Conclusion: The combination of TTNS and mirabegron represents a promising therapeutic strategy for women with overactive bladder, significantly improving symptoms and quality of life with a favorable safety profile. Further research with a larger sample size and long-term follow-up is warranted to confirm these findings and explore the underlying mechanisms of this combination therapy’s efficacy.

show abstract

“…The pathogenesis of OAB mainly includes non-neurogenic detrusor instability, overactive bladder, dysfunctions of urethra and pelvic floor muscles, abnormal hormone metabolisms and so on. In addition to screening tests, overactive bladder symptom score (OABSS) has been proved to be highly sensitive to the diagnosis of OAB [8]. Traditional treatments for OAB include bladder training, pelvic floor muscle training (PRMT), anticholinergic drug, sacral nerve stimulation (SNS) and surgery.…”

Section: Introductionmentioning

confidence: 99%

The therapeutic effect of neuromuscular electrical stimulation by different pulse widths for overactive bladder in elderly women: a randomized controlled study

Gai

et al. 2022

Ginekol Pol

View full text Add to dashboard Cite

Objectives: There have been a number of controversies about which treatment of neuromuscular electrical stimulation (NMES) is more beneficial for overactive bladder (OAB). An attempt to investigate the therapeutic effect of NMES with different pulse widths for OAB in elderly women has been made in this study. Material and methods:The postmenopausal elderly women without pelvic organ prolapse (POP) who received transvaginal NMES in Beijing Hospital from November 2020 to December 2020 were randomly divided into two groups (Group A and Group B). Patients from Group A accepted the treatment with NMES by pulse width of 300 µs and patients from Group B accepted the treatment with NMES by pulse width of 200 µs. Myoelectric potential of Type I and Type II muscle fibers at pelvic floor and overactive bladder symptom score (OABSS) were valued.Results: There were 46 patients eligible for the study and randomly divided into Group A and Group B, 23 patients for each group. OABSS were significantly reduced in both groups after the treatment of NEMS. And OABSS in Group A (after treated by pulse width of 300 µs) were significantly decreased greater than those in Group B (after treated with pulse width of 200 µs). Both Group A and Group B had no significant difference in the mean myoelectric potential at pre-resting state when compared before and after the treatment of NEMS. Myoelectric potential of Type I muscle fiber and the maximum myoelectric potential of Type II muscle fibers were significantly increased after the treatment of NEMS than before the treatment in the two groups, respectively. And myoelectric potential of Type I muscle fiber and the maximum myoelectric potential of Type II muscle fibers in group A (after treated with pulse width of 300 µs) were increased significantly much higher than those in Group B (after treated with pulse width of 200 µs). Conclusions:Comparing the indicators before and after the treatments of NMES, our study has preliminarily confirmed that NMES has its advantages in treating with OAB. And NMES by pulse width of 300 µs were more effective in improving pelvic floor muscle strength than NMES by pulse width of 200 µs.

show abstract

Case‐finding tools for the diagnosis of OAB in women: A narrative review

Cited by 5 publications

References 54 publications

Efficacy and Safety of Mirabegron Add-on Therapy After Failure With Solifenacin in Multiple Sclerosis Patients With Overactive Bladder: A Pilot Study

Efficacy and Safety of Mirabegron Add-on Therapy After Failure With Solifenacin in Multiple Sclerosis Patients With Overactive Bladder: A Pilot Study

Efficacy of the combination of transcutaneous tibial nerve stimulation(TTNS) and mirabegron in women with overactive bladder: a prospective randomized controlled trial

The therapeutic effect of neuromuscular electrical stimulation by different pulse widths for overactive bladder in elderly women: a randomized controlled study

Contact Info

Product

Resources

About